PRÉ-ENTRAÎNEMENT

PRÉ-ENTRAÎNEMENT è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. Nessuna delle regole che verifichiamo rileva punti sulla composizione dichiarata; le dosi di vitamine e minerali non sono pubblicate da Compl’Alim e quindi non vengono controllate.

Marca

non indicata

Responsabile dell’immissione in commercio

Amazon EU SARL

Stato

Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)

Forma

Polvere

Dose giornaliera

10g

Sconsigliato (secondo il fabbricante)

Adolescenti (sotto i 18 anni), Donne che allattano, Allergia ai derivati salicilici, Pregresso tumore al seno, Calcoli renali, Deficit congenito di G6PD (favismo), Assunzione lontano dai pasti, Bambini (sotto i 12 anni), Bambini piccoli (da 1 a 3 anni), Donne in gravidanza, Ipertensione, Insufficienza renale, Malattia renale, Lattanti (sotto 1 anno), Consumo concomitante di alcol, Uso concomitante di un contraccettivo, Problemi cardiaci, Problemi al fegato, In trattamento con anticoagulanti, In trattamento con antidepressivi, In trattamento con antidiabetici, In trattamento antipertensivo, In trattamento farmacologico, In trattamento per la tiroide, Ulcera (stomaco o duodeno)

Obiettivi dichiarati dal fabbricante (non sono indicazioni autorizzate)

Sport

Aromi

Traduzione non disponibile. Testo originale, lingua: francese.

Saveur fruit

Compl’Alim, dichiarazioni di integratori alimentari · 2019-10-07T14:00:00+02:00

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

• Créatine monohydrate
  Leggere l'avvertenza, quando si applica e gli studi citati

  Testo originale ufficiale in inglese.

  Creatine Monohydrate

  Via di somministrazione: Oral

  Precauzioni e avvertenze

  When using this product you may gain weight (Volek and Rawson 2004; Bemben et al. 2001; Mihic et al. 2000).

  Fonti citate da Health Canada (3)

  • Bemben MG, Bemben DA, Loftiss DD, Knehans AW. 2001. Creatine supplementation during resistance training in college football athletes. Medicine & Science in Sports & Exercise 33(10):1667-1673.
  • Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. 2000. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Medicine & Science in Sports and Exercise 32(2):291-296.
  • Volek JS, Rawson ES. 2004. Scientific basis and practical aspects of creatine supplementation for athletes. Nutrition 20(7-8):609-614.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (Pline and Smith 2005; Pritchard and Kalra 1998).

  Fonti citate da Health Canada (2)

  • Pline KA, Smith CL. 2005. The effect of creatine intake on renal function. The Annals of Pharmacotherapy 39(6):1093-1096.
  • Pritchard NR, Kalra PA. 1998. Renal dysfunction accompanying oral creatine supplements. The Lancet 351(9111):1252-1253.

  Monografia di Health Canada del 28 giugno 2024

• Tyrosine
  Leggere l'avvertenza, quando si applica e gli studi citati

  Testo originale ufficiale in inglese.

  L-TYROSINE

  Via di somministrazione: Oral

  Precauzioni e avvertenze

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

  Monografia di Health Canada del 30 gennaio 2026

• Caféine
  Leggere l'avvertenza, quando si applica e gli studi citati

  Testo originale ufficiale in inglese.

  CAFFEINE

  Via di somministrazione: Oral (Higdon and Frei 2006)

  Precauzioni e avvertenze

  Si applica ai prodotti: providing 100 mg to 400 mg caffeine, per day1.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

  Fonti citate da Health Canada (7)

  • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Studio randomizzato
  • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
  • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Articolo di revisione
  • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Studio clinico
  • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analisi
  • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analisi

  1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

  Si applica ai prodotti: providing more than 300 mg caffeine, per day.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

  Fonti citate da Health Canada (1)

  • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Articolo di revisione

  Si applica ai prodotti: providing 400 mg or more caffeine, per day.

  When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

  Fonti citate da Health Canada (8)

  • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
  • Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Caso clinico
  • Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Studio randomizzato
  • FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
  • Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Studio randomizzato
  • NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
  • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Caso clinico
  • Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.

  Controindicazioni

  Si applica ai prodotti: providing more than 400 mg caffeine per day.

  Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

  Fonti citate da Health Canada (7)

  • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Studio randomizzato
  • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
  • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Articolo di revisione
  • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Studio clinico
  • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analisi
  • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analisi

  Reazioni avverse note

  Condizione di applicazione: All products.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

  Fonti citate da Health Canada (2)

  • Hinrichs R, Hunzelmann N, Ritzkowsky A, Zollner TM, Krieg T, Scharffetter-Kochanek K. Caffeine hypersensitivity. Allergy 2002;57(9):859-860. PubMed Caso clinico
  • Infante S, Baeza ML, Calvo M, De Barrio M, Rubio M, Herrero T. Anaphylaxis due to caffeine. Allergy 2003;58(7):681-682. PubMed Caso clinico

  Si applica ai prodotti: providing 200 mg or more caffeine, per day.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

  Fonti citate da Health Canada (1)

  • Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.

  Si applica ai prodotti: providing more than 400 mg caffeine, per day.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

  Fonti citate da Health Canada (3)

  • IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
  • Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Articolo di revisione
  • Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Articolo di revisione

  Condizione di applicazione: All products except those making a diuretic claim1.

  When using this product diuretic effect may occur.

  1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

  Monografia di Health Canada del 19 dicembre 2025